Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 82.68
(-0.39%)
INR 82.68
(-0.39%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 111.62 Million INR | -98.52% |
| 2022 | 7.53 Billion INR | -11.22% |
| 2021 | 8.48 Billion INR | -4.11% |
| 2020 | 8.84 Billion INR | -0.76% |
| 2019 | 8.91 Billion INR | -7.69% |
| 2018 | 9.65 Billion INR | 85.51% |
| 2017 | 5.2 Billion INR | -12.08% |
| 2016 | 5.92 Billion INR | -13.48% |
| 2015 | 6.84 Billion INR | -16.16% |
| 2014 | 8.16 Billion INR | -15.37% |
| 2013 | 9.64 Billion INR | 17.87% |
| 2012 | 8.18 Billion INR | 15.07% |
| 2011 | 7.11 Billion INR | 18.63% |
| 2010 | 5.99 Billion INR | 1.88% |
| 2009 | 5.88 Billion INR | 55.07% |
| 2008 | 3.79 Billion INR | 21.18% |
| 2007 | 3.13 Billion INR | 7.48% |
| 2006 | 2.91 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 111.62 Million INR | 0.0% |
| 2023 Q2 | 7.28 Billion INR | 0.0% |
| 2023 FY | 111.62 Million INR | -98.52% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 7.53 Billion INR | -11.22% |
| 2022 Q4 | 7.53 Billion INR | 0.0% |
| 2022 Q2 | 8.11 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 8.48 Billion INR | -4.11% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 8.76 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 8.48 Billion INR | 0.0% |
| 2020 Q4 | 8.84 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 8.84 Billion INR | -0.76% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 8.9 Billion INR | 0.0% |
| 2019 Q4 | 8.91 Billion INR | 0.0% |
| 2019 Q2 | 9.66 Billion INR | 0.0% |
| 2019 FY | 8.91 Billion INR | -7.69% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 9.65 Billion INR | 85.51% |
| 2018 Q4 | 9.65 Billion INR | 0.0% |
| 2017 FY | 5.2 Billion INR | -12.08% |
| 2016 FY | 5.92 Billion INR | -13.48% |
| 2015 FY | 6.84 Billion INR | -16.16% |
| 2014 FY | 8.16 Billion INR | -15.37% |
| 2013 FY | 9.64 Billion INR | 17.87% |
| 2012 Q4 | 8.18 Billion INR | 0.0% |
| 2012 FY | 8.18 Billion INR | 15.07% |
| 2012 Q2 | 14.73 Billion INR | 0.0% |
| 2011 FY | 7.11 Billion INR | 18.63% |
| 2010 FY | 5.99 Billion INR | 1.88% |
| 2009 FY | 5.88 Billion INR | 55.07% |
| 2008 FY | 3.79 Billion INR | 21.18% |
| 2007 FY | 3.13 Billion INR | 7.48% |
| 2006 FY | 2.91 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 82.248% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.477% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 24.378% |
| Granules India Limited | 689.71 Million INR | 83.816% |
| Indoco Remedies Limited | 3.51 Billion INR | 96.826% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | 52.54% |
| Alkem Laboratories Limited | 400 Million INR | 72.094% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -3031.164% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -301.013% |
| Bajaj HealthCare Limited | 650.34 Million INR | 82.836% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 68.638% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 98.136% |
| Eris Lifesciences Limited | 6.54 Billion INR | 98.295% |
| FDC Limited | 2.46 Million INR | -4426.602% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 92.641% |
| Gufic Biosciences Limited | 1.53 Billion INR | 92.75% |
| Ipca Laboratories Limited | 5.8 Billion INR | 98.077% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -47.712% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 93.917% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 98.703% |
| Lupin Limited | 1.55 Billion INR | 92.811% |
| Mankind Pharma Limited | 248.67 Million INR | 55.112% |
| Medicamen Biotech Limited | 12.55 Million INR | -789.096% |
| Medico Remedies Limited | 8.67 Million INR | -1187.2% |
| Megasoft Limited | 1.35 Billion INR | 91.774% |
| NATCO Pharma Limited | 53 Million INR | -110.615% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.551% |
| RPG Life Sciences Limited | -30.3 Million INR | 468.403% |
| Sigachi Industries Limited | 265.79 Million INR | 58.003% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -739.293% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 47.434% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 9257.178% |
| Unichem Laboratories Limited | 382.22 Million INR | 70.795% |
| Wanbury Limited | 820 Million INR | 86.387% |
| Windlas Biotech Limited | 20.18 Million INR | -453.152% |
| ZIM Laboratories Limited | 356 Million INR | 68.645% |
| Zydus Lifesciences Limited | 251 Million INR | 55.527% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -4.715% |
| Divi's Laboratories Limited | 20 Million INR | -458.13% |
| Hester Biosciences Limited | 1.81 Billion INR | 93.859% |
| Procter & Gamble Health Limited | 68.8 Million INR | -62.247% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -699.155% |
| Bal Pharma Limited | 363.82 Million INR | 69.319% |
| Strides Pharma Science Limited | 6.71 Billion INR | 98.338% |
| Venus Remedies Limited | 386.8 Million INR | 71.141% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -27806.5% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 92.044% |
| Shilpa Medicare Limited | 5.6 Billion INR | 98.007% |
| Aarti Drugs Limited | 2.75 Billion INR | 95.946% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 98.894% |
| Valiant Laboratories Limited | 746.63 Million INR | 85.049% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 52.781% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 89.452% |
| Themis Medicare Limited | 267.74 Million INR | 58.308% |
| Hikal Limited | 4.22 Billion INR | 97.36% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.304% |
| Sequent Scientific Limited | 1.42 Billion INR | 92.179% |
| Novartis India Limited | 50.7 Million INR | -120.17% |
| Wockhardt Limited | 8.91 Billion INR | 98.747% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.648% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 75.15% |
| Morepen Laboratories Limited | 33.64 Million INR | -231.825% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 16.411% |